SAN DIEGO, Aug. 06, 2026 (GLOBE NEWSWIRE) --

圣迭戈，2026年8月6日（环球新闻社）--

BlossomHill Therapeutics, Inc.

BlossomHill Therapeutics, Inc.

, (“BlossomHill Therapeutics”), a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to develop innovative small molecule medicines for the treatment of cancer, today announced the pricing of its upsized initial public offering of 9,375,000 shares of common stock at a price to the public of $16.00 per share.

BlossomHill Therapeutics（“BlossomHill Therapeutics”）是一家处于临床阶段的生物制药公司，采用有意识的、基于化学的方法开发用于治疗癌症的创新小分子药物。该公司今日宣布了其扩大规模后的首次公开募股（IPO）的定价：以每股16.00美元的价格向公众发行9,375,000股普通股。

The gross proceeds to BlossomHill Therapeutics from the offering, before deducting underwriting discounts and commissions and offering expenses payable by BlossomHill Therapeutics, are expected to be $150.0 million, excluding any exercise of the underwriters’ option to purchase additional shares. In addition, BlossomHill Therapeutics has granted the underwriters a 30-day option to purchase up to an additional 1,406,250 shares of common stock at the public offering price, less underwriting discounts and commissions.

在不扣除承销折扣、佣金以及由BlossomHill Therapeutics支付的发行费用的情况下，预计BlossomHill Therapeutics从本次发行中获得的总收益为1.5亿美元，该金额未包含承销商行使额外购股权的任何影响。此外，BlossomHill Therapeutics已授予承销商一项为期30天的选择权，允许其以公开发行价格减去承销折扣和佣金的价格，额外购买最多1,406,250股普通股。

All of the shares of common stock are being offered by BlossomHill Therapeutics..

BlossomHill Therapeutics 正在发售所有普通股股份。

The shares are expected to begin trading on The Nasdaq Global Select Market on August 7, 2026, under the ticker symbol “BLSM.” The offering is expected to close on August 10, 2026, subject to the satisfaction of customary closing conditions.

预计该等股份将于2026年8月7日在纳斯达克全球精选市场开始交易，股票代码为“BLSM”。在满足惯例交割条件的前提下，预计本次发行将于2026年8月10日完成交割。

J.P. Morgan, Leerink Partners and Guggenheim Securities are acting as lead book-running managers for the offering. LifeSci Capital and H.C. Wainwright & Co. are acting as joint book-running managers for the offering.

摩根大通、Leerink Partners 和 Guggenheim Securities 担任此次发行的牵头账簿管理人。LifeSci Capital 和 H.C. Wainwright & Co. 担任此次发行的联合账簿管理人。

Registration statements relating to these securities have been filed with the U.S. Securities and Exchange Commission (SEC) and became effective on August 6, 2026. Copies of the registration statements can be accessed through the SEC’s website at www.sec.gov. This offering is being made only by means of a prospectus forming part of the registration statements relating to these securities.

与这些证券相关的注册声明已提交至美国证券交易委员会（SEC），并于2026年8月6日生效。注册声明的副本可通过SEC网站www.sec.gov获取。本次发行仅通过构成与这些证券相关的注册声明一部分的招股说明书进行。

When available, copies of the final prospectus relating to the initial public offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525 ext.

如有提供，与首次公开发行相关的最终招股说明书副本可从以下机构获取：摩根大通证券有限责任公司（转交 Broadridge Financial Solutions，地址：纽约州埃奇伍德长岛大道 1155 号，邮编 11717），或通过电子邮件发送至 prospectus-eq_fi@jpmchase.com 和 postsalemanualrequests@broadridge.com；Leerink Partners LLC（收件人：承销团部门，地址：马萨诸塞州波士顿州街 53 号 40 层，邮编 02109），或通过电话 (800) 808-7525 分机联系。

6105 or by email at syndicate@leerink.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Ave., 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at .

6105，或通过电子邮件发送至 syndicate@leerink.com；或 Guggenheim Securities, LLC，收件人：股票承销部，地址：330 Madison Ave., 8th Floor, New York, NY 10017，电话：(212) 518-9544，或通过电子邮件发送至 。

GSEquityProspectusDelivery@guggenheimpartners.com

GSEquityProspectusDelivery@guggenheimpartners.com

.

。

This press release does not constitute an offer to sell, or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or jurisdiction.

本新闻稿不构成出售要约，也不构成购买这些证券的要约邀请；在任何州或司法管辖区，在根据该州或司法管辖区的证券法进行注册或资格认定之前，若此类要约、邀请或销售属非法，则不得在该州或司法管辖区销售这些证券。

Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended..

任何要约、招揽或购买要约，或任何证券销售，均将根据经修订的《1933年证券法》的注册要求进行。

About BlossomHill Therapeutics

关于BlossomHill Therapeutics

BlossomHill Therapeutics, Inc. is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop innovative small molecule medicines that address significant unmet medical needs in cancer treatment. Founded and led by industry veteran J. Jean Cui, Ph.D., with her proven track record in oncology drug design and development – including three FDA-approved drugs – BlossomHill Therapeutics applies cutting-edge science to address key oncogenic drivers and improve patient outcomes in difficult-to-treat cancers.

BlossomHill Therapeutics, Inc. 是一家处于临床阶段的生物制药公司，采用有意识的、基于化学的方法来设计和开发创新的小分子药物，以满足癌症治疗领域尚未满足的重大医疗需求。公司由行业资深专家崔晶晶博士（J. Jean Cui, Ph.D.）创立并领导，她在肿瘤药物设计与开发方面拥有经证实的卓越记录，包括三款获得美国食品药品监督管理局（FDA）批准的药物。BlossomHill Therapeutics 运用前沿科学，针对关键的致癌驱动因素，改善难治性癌症患者的治疗结局。

The company’s lead clinical programs include BH-30643, an investigational, non-covalent, macrocyclic, brain active, mutant-selective OMNI-EGFR inhibitor for the treatment of EGFR-mutant non-small cell lung cancer (NSCLC) with an initial development focus in the C797S resistance population after 3rd generation EGFR TKI treatment, and BH-30236, an investigational macrocyclic CDC-like kinase (CLK) inhibitor initially being developed for the treatment of relapsed or refractory acute myeloid leukemia (R/R AML) or higher-risk myelodysplastic syndrome (HR-MDS) and BH-501284, our preclinical, non-covalent, selective, pan-KRAS Switch II inhibitor for potential future development in diverse KRAS-mutant tumors.

公司的主要临床项目包括：BH-30643，一种在研的非共价、大环、具有脑活性且突变选择性的OMNI-EGFR抑制剂，用于治疗EGFR突变的非小细胞肺癌（NSCLC），其初始开发重点为第三代EGFR酪氨酸激酶抑制剂（TKI）治疗后出现C797S耐药突变的患者群体；BH-30236，一种在研的大环CDC样激酶（CLK）抑制剂，初始开发用于治疗复发或难治性急性髓系白血病（R/R AML）或高危骨髓增生异常综合征（HR-MDS）；以及BH-501284，公司处于临床前阶段的非共价、选择性泛KRAS Switch II抑制剂，用于未来在多种KRAS突变肿瘤中的潜在开发。

BlossomHill Therapeutics is headquartered in San Diego, California..

BlossomHill Therapeutics 的总部位于加利福尼亚州圣地亚哥。

Company Contact:

公司联系人：

Michael Moore, BlossomHill Therapeutics

迈克尔·摩尔，BlossomHill Therapeutics

michael.moore@bhtherapeutics.com

michael.moore@bhtherapeutics.com

Media:

媒体：

Ashlea Kosikowski, 1AB

阿什莉亚·科西科夫斯基，1AB

ashlea@1abmedia.com

ashlea@1abmedia.com